Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Capital Expenditures (2020 - 2024)

Ovid Therapeutics (OVID) has disclosed Capital Expenditures for 5 consecutive years, with -$26000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Capital Expenditures rose 62.86% year-over-year to -$26000.0, compared with a TTM value of -$26000.0 through Sep 2025, down 156.52%, and an annual FY2024 reading of $90000.0, up 125.0% over the prior year.
  • Capital Expenditures was -$26000.0 for Q4 2024 at Ovid Therapeutics, down from $97000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $973039.0 in Q4 2022 and bottomed at -$70000.0 in Q4 2023.
  • Average Capital Expenditures over 5 years is $105989.8, with a median of $19000.0 recorded in 2024.
  • The sharpest move saw Capital Expenditures crashed 132.25% in 2021, then surged 1683.8% in 2022.
  • Year by year, Capital Expenditures stood at $237358.0 in 2020, then dropped by 24.75% to $178608.0 in 2021, then soared by 444.79% to $973039.0 in 2022, then plummeted by 107.19% to -$70000.0 in 2023, then skyrocketed by 62.86% to -$26000.0 in 2024.
  • Business Quant data shows Capital Expenditures for OVID at -$26000.0 in Q4 2024, $97000.0 in Q2 2024, and $19000.0 in Q1 2024.